Title:
COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2012/015741
Kind Code:
A3
Abstract:
The present invention relates to a method of treating cancer by administering an IGF-1R specific antibody in combination with an anti-cancer agent exemplified by an Akt pathway inhibitor. The first and second amounts together comprise a therapeutically effective amount.
Inventors:
SATHYANARAYANAN SRIRAM (US)
WINTER CHRISTOPHER (US)
VALENTINE ERIN (US)
BLOECHER ANDREW (US)
WINTER CHRISTOPHER (US)
VALENTINE ERIN (US)
BLOECHER ANDREW (US)
Application Number:
PCT/US2011/045191
Publication Date:
March 29, 2012
Filing Date:
July 25, 2011
Export Citation:
Assignee:
MERCK SHARP & DOHME (US)
SATHYANARAYANAN SRIRAM (US)
WINTER CHRISTOPHER (US)
VALENTINE ERIN (US)
BLOECHER ANDREW (US)
SATHYANARAYANAN SRIRAM (US)
WINTER CHRISTOPHER (US)
VALENTINE ERIN (US)
BLOECHER ANDREW (US)
International Classes:
A61K39/395
Foreign References:
| US7241444B2 | 2007-07-10 | |||
| US20020081294A1 | 2002-06-27 | |||
| US20080089892A1 | 2008-04-17 | |||
| US20090130105A1 | 2009-05-21 |
Other References:
BERTRAND ET AL.: "Synergy between an IGF-1 R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.", LEUKEMIA, vol. 20, no. 7, 2006, pages 1254 - 1260, XP055076759, DOI: doi:10.1038/sj.leu.2404217
HIRAI ET AL.: "MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.", MOL CANCER THER, vol. 9, no. 7, 22 June 2010 (2010-06-22), pages 1956 - 1967, XP055074270, DOI: doi:10.1158/1535-7163.MCT-09-1012
SCARTOZZI ET AL.: "Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.", CURR OPIN MOL THER, vol. 12, no. 3, June 2010 (2010-06-01), pages 361 - 371
HIRAI ET AL.: "MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.", MOL CANCER THER, vol. 9, no. 7, 22 June 2010 (2010-06-22), pages 1956 - 1967, XP055074270, DOI: doi:10.1158/1535-7163.MCT-09-1012
SCARTOZZI ET AL.: "Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.", CURR OPIN MOL THER, vol. 12, no. 3, June 2010 (2010-06-01), pages 361 - 371
Attorney, Agent or Firm:
MERCK SHARP & DOHME CORP. (Rahway, NJ, US)
Download PDF:
Previous Patent: RESIST FORTIFICATION FOR MAGNETIC MEDIA PATTERNING
Next Patent: AN APPARATUS AND METHOD FOR UTILIZING THERMAL ENERGY
Next Patent: AN APPARATUS AND METHOD FOR UTILIZING THERMAL ENERGY